Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Launched by MINNEAPOLIS HEART INSTITUTE FOUNDATION · Mar 23, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a type of medication called SGLT2 inhibitors to see if it can help improve heart function and reduce the size of the heart after a heart attack, specifically a type called STEMI. If you are an adult who has just experienced your first STEMI and have some heart function issues, you may be eligible to participate. To qualify, you should have had a successful procedure to open up the blocked artery and have certain test results showing your heart's condition.

If you decide to join the study, you'll take either the SGLT2 medication or a placebo (a non-active pill) once a day for six months. You’ll also have a heart MRI during your hospital stay, follow-up phone calls at one and three months, and another MRI with a clinic visit at six months. This is a single-center study, meaning it will take place at just one location. The study is currently recruiting participants, and everyone is welcome to apply, regardless of gender. Your participation could help improve treatments for heart attack patients in the future!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with their first STEMI (\>18 years) who underwent successful primary PCI and able to give informed consent
• • At least mild LV dysfunction (LVEF \< 50%) on echocardiogram, cMRI or Left Ventriculargram following PCI
• • Infarct size that is \> 10% of LV mass
• • The presence of MVO that is \> 10% of infarct size
• Exclusion Criteria:
• • Contraindication to cardiac MRI
• • Life expectancy \< 1 year
• • Previous CABG or Valve Surgery
• • Previous STEMI
• • Pregnant or planning to become pregnant or lactating women
• • Cardiogenic shock (not resolved)
• • Atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding PVCs)
• • GFR\<30 ml/min/1.73m2 or end-stage renal disease on dialysis
• • Type 1 diabetes mellitus or history of diabetic ketoacidosis
• • Type I or II diabetes with insulin use
• • Prior intolerance of SGLT2 inhibitors
• • Current use of SGLT2 inhibitors (randomized patients only)
• • Contraindications to gadolinium